Particle Therapy and CyberKnife SBRT: Different Roles in Local Cancer Treatment
Particle therapy and CyberKnife SBRT are both forms of local radiation treatment, but they are not the same.
They differ in beam physics, dose distribution, motion management, treatment planning, and the clinical situations in which they may be considered.
CyberKnife SBRT uses highly focused photon radiation. It is often considered for small, well-defined tumors where a high dose can be delivered in a limited number of sessions.
Particle therapy uses proton or carbon-ion beams. Its main physical advantage is dose concentration at a defined depth, with reduced unnecessary dose beyond the target area.
The practical difference is not simply whether one technology is more advanced than the other.
The important question is which approach can deliver an effective dose to the tumor while keeping nearby normal tissues within safe limits.
General Comparison
Aspect | Particle Therapy | CyberKnife SBRT |
Radiation type | Proton or carbon-ion beams | Photon radiation |
Dose distribution | Can reduce dose beyond the target area | Photon exit dose remains a planning consideration |
Motion tracking | Depends on system and treatment site | Strong real-time tracking capability |
Organ protection | May be relevant when tumors are near critical organs | May be appropriate when organ-at-risk limits can be safely met |
Treatment role | Selected tumors where dose distribution or tissue protection is important | Small, well-defined lesions suitable for stereotactic treatment |
Particle therapy may be reviewed in selected cases involving tumors near organs at risk, re-irradiation, larger or irregular targets, centrally located tumors, or certain radiation-resistant tumor types.
CyberKnife SBRT may be appropriate for selected small, well-circumscribed lesions, especially when motion tracking is important and nearby organ dose limits can be safely achieved.
This comparison should not be understood as a ranking between technologies.
The appropriate option depends on cancer type, tumor size and location, prior treatment history, organ-at-risk constraints, imaging findings, motion considerations, and the patient’s overall condition.
Recent imaging files, such as CT, MRI, or PET-CT in DICOM format, are often essential for treatment planning review.
APIS helps coordinate communication and document submission to Korean hospitals for selected international cases.
* Final treatment decisions are determined solely by the treating hospitals and physicians.
